An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression

Summary & key facts

This paper looks across many kinds of studies about ketamine and suggests that putting all the findings together could make ketamine treatment for depression work better. Researchers say ketamine acts in several different ways in the brain. It has been shown over the last twenty years to reduce depression symptoms quickly and for a lasting time, even when other treatments failed. The authors recommend combining those different findings into practical steps, like adjusting dose with brain monitoring, using good care for the treatment setting, adding chosen music, checking inflammation and brain activity, and timing therapy sessions to match when the brain is most likely to grow new connection

Key facts:

• Research over the last two decades has found ketamine to be a safe, effective, fast-acting, and lasting antidepressant for many people, including those whose depression did not get better with other treatments.
• Ketamine works in several different ways in the brain, not just one.
• One way ketamine works is by blocking certain brain receptors called NMDA receptors, which is tied to rapid improvements in mood.
• Ketamine can also stimulate growth of new connections between brain cells and increase the brain's ability to change. This is sometimes called synaptogenesis or increased neuroplasticity.
• Ketamine has anti-inflammatory effects in the brain, which might help people whose depression is linked to inflammation.
• Some researchers describe ketamine as producing a temporary state of more varied brain activity, sometimes called a high-entropy brain state, which may help break rigid negative thinking.
• The scientific work on ketamine has split into separate areas that mostly did not communicate with each other. The authors say bringing those areas together could help make treatments better.
• The paper lists practical steps that could improve care, such as: teaching patients about all of ketamine's actions; using brain measurements to pick doses that create the desired brain state; managing the treatment environment and support
• These suggested steps are proposals based on combining existing research. They are not presented as fully proven clinical rules and would need coordinated research to test whether they improve outcomes.

Abstract

Research over the last two decades has established ketamine as a safe, effective, fast-acting, and sustained antidepressant that significantly reduces adverse symptoms associated with depression, even in patients who are treatment resistant. Much of this research has evolved within the framework of several independent branches of scientific inquiry: in addition to the study of ketamine is a non-selective NMDAR antagonist with rapid antidepressant effects, it has also been found effective as a psychoplastogen that stimulates synaptogenesis and increases neuroplasticity, as a powerful anti-inflammatory that may improve inflammation-related depressive symptoms, as a substance that induces beneficial high entropy brain states, and as a subjectively impactful psychedelic agent. Each branch of inquiry has generated independent evidence of ketamine's efficacy but has advanced without substantive coordination or communication with other lines of inquiry. Integrative research that considers these branches of research together may lead toward a better understanding of ketamine's effects and improved treatment protocols and clinical outcomes. Such an overview can inform more comprehensive patient care through: (a) informed patient psychoeducation that encompasses all of ketamine's mechanisms of action; (b) calibration of optimal dosage to ensure induction and maintenance of high entropy brain states during each ketamine session utilizing EEG measurement; (c) Improved management of emergence side effects through proper care for set and setting; (d) inclusion of pre-selected appropriate music to enhance the emotional experience; (e) increased monitoring of ketamine effects on cortical activity, inter-hemispheric imbalance, and inflammation-related levels of cytokines to further improvements in ketamine protocols; and (f) appropriate timing of any adjunctive psychotherapy sessions to coincide with peak neurogenesis at 24-48 h post ketamine treatment.

Topics

Psychedelics and Drug Studies Treatment of Major Depression Tryptophan and brain disorders

Categories

Health Sciences Medicine Pharmacology

Tags

Antidepressant Anxiety Ketamine Medicine Psychiatry Psychology Psychotherapist

Substances

Ketamine

Conditions & symptoms

Anxiety Lack of energy or motivation Poor sleep Sadness or low mood